AXIM Biotech hoping for 2017 release of its pain-relief gum, MedChew Rx, moving into clinical testing
MedChew Rx, by AXIM Biotechnology, Inc., the world’s first patented cannabinoid release chewing gum for pain and spasticity in multiple sclerosis (MS), is moving into clinical testing. If all goes well, the company plans for a global release date of 2017.
Medical cannabis is believed to have considerable promise as a therapy for difficult-to-treat pain associated with disorders like MS and other conditions that cause nerve pain. AXIM Biotech, based in New York and Ridderkerk, the Netherlands, says that if approved as expected by the FDA (U.S. Food and Drug Administration) and the EMA (European Medicines Agency), MedChew Rx — formulated with 5 mg of cannabidiol (CBD) and 5 mg of tetrahydrocannabinol (THC) — will be marketed as a pharmaceutical drug for treating MS.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
MS Views and News
helps to provide educational information for persons affected by MS
Keep current with Multiple Sclerosis news and information
by opting-in to our website: click here – thank you
.===================================
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews